戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ) provides the rationale for treatments with anticholinesterases.
2 ma is the likely target for schistosomicidal anticholinesterases.
3                      These were assessed for anticholinesterase action against freshly prepared human
4 were obtained by known procedures, and their anticholinesterase actions were similarly quantified aga
5 mass of 250-320 g/mol have high potential of anticholinesterase activities and are valuable for futur
6                                 Finally, the anticholinesterase activities of intermediates N1, N8-bi
7                                          The anticholinesterase activities of N(8)-nor- and N(8)-subs
8 ular weights of aglycone compounds and their anticholinesterase activities.
9 icetin, chrysin, and luteolin) showed strong anticholinesterase activities.
10 xidant, antidiabetic, anti-inflammatory, and anticholinesterase activities.
11 n for the development of new drugs that have anticholinesterase activity and may be used for the trea
12  activity and a steroidal glycoalkaloid with anticholinesterase activity and suggest spatial mutual e
13                        Both compounds lacked anticholinesterase activity in concentrations up to 30 m
14 e activation, nor was it associated with the anticholinesterase activity of the drug.
15                 An analysis of the structure/anticholinesterase activity relationship of the describe
16           To elucidate further the structure/anticholinesterase activity relationship of the describe
17 compounds possessed moderate but less potent anticholinesterase activity, with the same selectivity a
18 ationship between antioxidant activities and anticholinesterase activity.
19 rred following administration of eserine, an anticholinesterase agent.
20    The compounds showed significant in vitro anticholinesterase (anti-ChE) activity, the most potent
21                                        These anticholinesterase compounds are classically considered
22 urotransmission in the OB by addition of the anticholinesterase drug neostigmine (20 mM) sharpened th
23 uine, the antifolate drug metoprine, and the anticholinesterase drug tacrine (an early drug for Alzhe
24 d Alzheimer's disease; four patients entered anticholinesterase drug trials.
25 arget is key for the development of improved anticholinesterase drugs and potentially a novel vaccine
26 e and fruit-methanol extracts exerted potent anticholinesterase effects (66.4 +/- 0.65% to 97.7 +/- 0
27 re more potent than, or similarly potent to, anticholinesterases in current clinical use, providing n
28           Recent studies have suggested that anticholinesterases including organophosphates and carba
29  We further compared the affinity of various anticholinesterases including organophosphorous nerve ag
30  were strongly ameliorated on treatment with anticholinesterase inhibitor in another patient.
31 h is the target of poisonous organophosphate anticholinesterase insecticides such as the parathion me
32 n cholinergic functions and is the target of anticholinesterase insecticides, whereas TcAce2 plays an
33 ion and increased larval susceptibilities to anticholinesterase insecticides.
34  dosing of neuromuscular blocking agents and anticholinesterases is often inappropriate and adequacy
35 Patients did not show long-term benefit from anticholinesterase medication and sometimes worsened, an
36 oth autoimmune and genetic myasthenias where anticholinesterase medication is a standard treatment.
37 e beta2-adrenergic agonist salbutamol to the anticholinesterase medication pyridostigmine.
38 ts with acetylcholine receptor deficiency on anticholinesterase medication that demonstrates a sustai
39 ffer in their sensitivity to the therapeutic anticholinesterase metrifonate.
40 e detection and prediction tools, the potent anticholinesterase neurotoxin, guanitoxin, is not presen
41 ents to elucidate the mechanism of action of anticholinesterases on the nicotinic AChR in rat clonal
42 ither with a carbamate or an organophosphate anticholinesterase pesticide showed significant regional
43 ed a series of novel analogues of the potent anticholinesterases phenserine (2) and physostigmine (1)
44 and visual control tasks, using fMRI and the anticholinesterase physostigmine.
45  30-45 minutes of a seizurogenic dose of the anticholinesterase, soman.
46 and can be separated from alpha-tomatine, an anticholinesterase steroidal glycoalkaloid.
47 ion Class II-IV disease, and were on optimal anticholinesterase therapy with or without oral corticos
48 ns were not detected and patients respond to anticholinesterase treatments.
49 operties, chemical composition, antioxidant, anticholinesterase, tyrosinase inhibitory, and urease in